Trial reportNutrition & diabetes2026
Plasma proteomics analysis of vitamin C supplementation in people with type 2 diabetes.
Trial report in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence from randomised controlled trials shows that vitamin C (VC) supplementation may improve cardiometabolic health outcomes in people with type 2 diabetes (T2D). Plasma proteomics may help to further enhance our understanding of VC's therapeutic effects and biological mechanisms in T2D. Therefore, our aim was to explore the effects of VC supplementation on the plasma proteome in people with T2D.
methodsA double-blind, placebo-controlled, crossover trial was undertaken in people with T2D, who were administered 1000 mg/day VC or placebo for 4 months. Plasma proteins in 26 participants (22 male, 4 female, age 62.6 ± 6.5 years, HbA1c 60 ± 11 mmol/mol [7.6 ± 0.7%]) were quantified by liquid chromatography/mass spectrometry with data-independent acquisition. Differential protein expression was assessed for VC post-supplementation vs. control [pooling of all non-active conditions].
resultsTwelve proteins were significantly downregulated and three were upregulated following VC supplementation (|log2-fold change [FC]| ≥ 0.5; false discovery rate<0.05). These included proteins with functions in innate immunity, carbohydrate digestion, unfolded protein binding, and muscle contraction. Protein candidates that had the greatest magnitude decrease (|log2-FC| > 1) with VC supplementation were alpha-amylase 1 (AMY1), heat shock protein 75 kDa (TRAP1), myosin-1 (MYH1), and serum amyloid protein A1 (SAA1). Pathway enrichment revealed underrepresentation of unfolded protein binding, ATP binding, attenuation phase, and the innate immune system following VC supplementation. TRAP1, alpha-actin-1, Heat shock 70 kDa protein-1, and CD166 antigen were associated with previously reported improved blood-pressure outcomes following VC supplementation.
conclusionsVC supplementation significantly altered abundance of numerous proteins in plasma, with functions relating to the innate immune system, dietary carbohydrate digestion, and protein folding chaperone activity. We identified novel proteins responsive to VC supplementation and protein-clinical improvement correlations in people with T2D that require further exploration to understand their biological significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.